-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec recently, the Chilean Ministry of Health announced that the inactivated vaccine CoronaVac developed by Beijing Sinovac Biotechnology Co.
, Ltd.
(Sinovac) and a number of partners has been vaccinated nationwide in Chile.
Real-world data.
This is the largest real-world data to date to test the effectiveness of Kerrlive's protection.
The Chilean government conducted a follow-up study on the 10.
5 million people registered in the health system, comparing the results of the new coronavirus infection of people who have received one or two doses of the new crown vaccine with those who have not been vaccinated.
The results of the study showed that Kellyford's effectiveness in protecting symptomatic COVID-19 reached 67%, while the effectiveness of preventing patients from being hospitalized reached 85%.
Kerlaifu is an inactivated COVID-19 vaccine jointly developed by Kexing.
Chile is one of the earliest countries in the world to carry out large-scale COVID-19 vaccination.
At least 7.
6 million people have been vaccinated with at least one dose, and 5.
12 million have been vaccinated with two doses, reaching 33.
7% of the Chilean population.
Currently, the new crown vaccines vaccinated in Chile are mRNA vaccines jointly developed by Kellyford and Pfizer/BioNTech.
However, the proportion of the population vaccinated with Kellyford is much higher than that of mRNA vaccines (90.
9% vs.
9.
1%).
▲Chile's new crown vaccination situation (picture source: reference [2]) analysis of real-world new crown virus infection data from February 2 to April 1 this year shows that two doses of Kerr were completed 28 days apart After the vaccination, the vaccine's effectiveness in preventing symptomatic COVID-19 reached 67%, the effectiveness of preventing hospitalization reached 85%, the effectiveness of preventing entry into the intensive care unit (ICU) was 89%, and the effectiveness of preventing death was 80%.
▲Summary of the effectiveness of Kerlaifu in preventing COVD-19 (picture source: reference [2]) In addition, this study also demonstrates the importance of complete vaccination with two doses.
The researchers compared the protective efficacy of Kellyford in a part of the vaccinated population (14 days after the first dose of the vaccine) and those who completed two doses of the vaccine (14 days after the second dose of the vaccine).
They found that in terms of preventing symptomatic COVID-19, the protective effect of Kellyford in some vaccinated populations was only 16.
1%, and its effectiveness in fully vaccinated populations increased to 67.
0%; in terms of preventing hospitalization, some vaccinated populations The efficacy was 35.
7%, and the efficacy in the fully vaccinated population was increased to 84.
8%; in terms of preventing entry into the intensive care unit, the efficacy was 42.
7% in the partially vaccinated population and 88.
6% in the fully vaccinated population.
Dr.
Rafael Araos, who reported the results, said that this study did not directly assess the effectiveness of Kellyford against the newly emerged mutant strains of new coronaviruses.
However, at the time of this study, Chile was still in a period of high prevalence of new coronaviruses, and there were also epidemic viruses.
Contains mutant virus strains, so the results are still positive.
The Chilean Ministry of Health stated that it will continue to update the data in this study in the future.
Related reading: The detailed data of the Phase 3 clinical trial of Kexing inactivated vaccines are announced.
The protective efficacy can be observed 14 days after the first dose of vaccine.
The real world protection efficacy data of Kexing inactivated vaccines are released, from Brazil's reference materials for the epidemic of mutant virus strains: [ 1] China's Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection-Chile govt report.
Retrieved April 18, 2021, from -vaccine-67-effective-preventing-symptomatic-infection-2021-04-16/[2] Estudio sobre Sinovac realizado en Chile arrojó un 80% de efectividad para prevenir la muerte.
Retrieved April 18, 2021, from https:// www.
youtube.
com/watch?v=EogDv5lca5M[3] Beijing Kexing Zhongwei Biotechnology Co.
, Ltd.
New Coronavirus Inactivated Vaccine Kierlai Fu® Clinical Research Data Summary.
Retrieved April 18, 2021, from http:// www.
sinovac.
com.
cn/?optionid=468&auto_id=1877[4] Chile Says Sinovac Is 80% Effective Against Death From Covid.
Retrieved April 18, 2021, from Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation. If you need guidance on treatment plans, please go to a regular hospital for treatment.
, Ltd.
(Sinovac) and a number of partners has been vaccinated nationwide in Chile.
Real-world data.
This is the largest real-world data to date to test the effectiveness of Kerrlive's protection.
The Chilean government conducted a follow-up study on the 10.
5 million people registered in the health system, comparing the results of the new coronavirus infection of people who have received one or two doses of the new crown vaccine with those who have not been vaccinated.
The results of the study showed that Kellyford's effectiveness in protecting symptomatic COVID-19 reached 67%, while the effectiveness of preventing patients from being hospitalized reached 85%.
Kerlaifu is an inactivated COVID-19 vaccine jointly developed by Kexing.
Chile is one of the earliest countries in the world to carry out large-scale COVID-19 vaccination.
At least 7.
6 million people have been vaccinated with at least one dose, and 5.
12 million have been vaccinated with two doses, reaching 33.
7% of the Chilean population.
Currently, the new crown vaccines vaccinated in Chile are mRNA vaccines jointly developed by Kellyford and Pfizer/BioNTech.
However, the proportion of the population vaccinated with Kellyford is much higher than that of mRNA vaccines (90.
9% vs.
9.
1%).
▲Chile's new crown vaccination situation (picture source: reference [2]) analysis of real-world new crown virus infection data from February 2 to April 1 this year shows that two doses of Kerr were completed 28 days apart After the vaccination, the vaccine's effectiveness in preventing symptomatic COVID-19 reached 67%, the effectiveness of preventing hospitalization reached 85%, the effectiveness of preventing entry into the intensive care unit (ICU) was 89%, and the effectiveness of preventing death was 80%.
▲Summary of the effectiveness of Kerlaifu in preventing COVD-19 (picture source: reference [2]) In addition, this study also demonstrates the importance of complete vaccination with two doses.
The researchers compared the protective efficacy of Kellyford in a part of the vaccinated population (14 days after the first dose of the vaccine) and those who completed two doses of the vaccine (14 days after the second dose of the vaccine).
They found that in terms of preventing symptomatic COVID-19, the protective effect of Kellyford in some vaccinated populations was only 16.
1%, and its effectiveness in fully vaccinated populations increased to 67.
0%; in terms of preventing hospitalization, some vaccinated populations The efficacy was 35.
7%, and the efficacy in the fully vaccinated population was increased to 84.
8%; in terms of preventing entry into the intensive care unit, the efficacy was 42.
7% in the partially vaccinated population and 88.
6% in the fully vaccinated population.
Dr.
Rafael Araos, who reported the results, said that this study did not directly assess the effectiveness of Kellyford against the newly emerged mutant strains of new coronaviruses.
However, at the time of this study, Chile was still in a period of high prevalence of new coronaviruses, and there were also epidemic viruses.
Contains mutant virus strains, so the results are still positive.
The Chilean Ministry of Health stated that it will continue to update the data in this study in the future.
Related reading: The detailed data of the Phase 3 clinical trial of Kexing inactivated vaccines are announced.
The protective efficacy can be observed 14 days after the first dose of vaccine.
The real world protection efficacy data of Kexing inactivated vaccines are released, from Brazil's reference materials for the epidemic of mutant virus strains: [ 1] China's Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection-Chile govt report.
Retrieved April 18, 2021, from -vaccine-67-effective-preventing-symptomatic-infection-2021-04-16/[2] Estudio sobre Sinovac realizado en Chile arrojó un 80% de efectividad para prevenir la muerte.
Retrieved April 18, 2021, from https:// www.
youtube.
com/watch?v=EogDv5lca5M[3] Beijing Kexing Zhongwei Biotechnology Co.
, Ltd.
New Coronavirus Inactivated Vaccine Kierlai Fu® Clinical Research Data Summary.
Retrieved April 18, 2021, from http:// www.
sinovac.
com.
cn/?optionid=468&auto_id=1877[4] Chile Says Sinovac Is 80% Effective Against Death From Covid.
Retrieved April 18, 2021, from Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation. If you need guidance on treatment plans, please go to a regular hospital for treatment.
